IL164613A0 - Thienyl compounds - Google Patents

Thienyl compounds

Info

Publication number
IL164613A0
IL164613A0 IL16461304A IL16461304A IL164613A0 IL 164613 A0 IL164613 A0 IL 164613A0 IL 16461304 A IL16461304 A IL 16461304A IL 16461304 A IL16461304 A IL 16461304A IL 164613 A0 IL164613 A0 IL 164613A0
Authority
IL
Israel
Prior art keywords
compounds
thienyl compounds
thienyl
compositions
therapy
Prior art date
Application number
IL16461304A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201187A external-priority patent/SE0201187D0/xx
Priority claimed from SE0203608A external-priority patent/SE0203608D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL164613A0 publication Critical patent/IL164613A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL16461304A 2002-04-18 2004-10-14 Thienyl compounds IL164613A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0201187A SE0201187D0 (sv) 2002-04-18 2002-04-18 Thienyl compounds
SE0203608A SE0203608D0 (sv) 2002-12-04 2002-12-04 Thienyl compounds
PCT/SE2003/000614 WO2003087103A1 (en) 2002-04-18 2003-04-15 Thienyl compounds

Publications (1)

Publication Number Publication Date
IL164613A0 true IL164613A0 (en) 2005-12-18

Family

ID=29253789

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16461304A IL164613A0 (en) 2002-04-18 2004-10-14 Thienyl compounds

Country Status (16)

Country Link
US (3) US7186836B2 (enExample)
EP (1) EP1499615B1 (enExample)
JP (1) JP4511196B2 (enExample)
KR (1) KR20040099448A (enExample)
CN (1) CN1325499C (enExample)
AT (1) ATE477256T1 (enExample)
AU (1) AU2003224545B2 (enExample)
BR (1) BR0309342A (enExample)
CA (1) CA2482312A1 (enExample)
DE (1) DE60333746D1 (enExample)
ES (1) ES2348282T3 (enExample)
IL (1) IL164613A0 (enExample)
MX (1) MXPA04010193A (enExample)
NO (1) NO20044997L (enExample)
NZ (1) NZ535978A (enExample)
WO (1) WO2003087103A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
KR100614900B1 (ko) 2001-10-02 2006-08-25 파마시아 앤드 업존 캄파니 엘엘씨 질병의 치료를 위한 아자비시클릭-치환된 융합-헤테로아릴화합물
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
KR20040099447A (ko) * 2002-04-18 2004-11-26 아스트라제네카 아베 푸릴 화합물
AU2003224545B2 (en) * 2002-04-18 2009-08-13 Astrazeneca Ab Thienyl compounds
CN100494202C (zh) * 2003-10-21 2009-06-03 阿斯利康(瑞典)有限公司 螺呋喃并吡啶芳基衍生物
US7045530B2 (en) 2003-12-22 2006-05-16 Abbott Laboratories Spirocyclic quinuclidinic ether derivatives
TW200813067A (en) * 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009154563A1 (en) 2008-06-20 2009-12-23 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
ES2570657T3 (es) 2010-05-17 2016-05-19 Forum Pharmaceuticals Inc Una forma cristalina de hidrocloruro de (R)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidrato
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
WO2013169646A1 (en) 2012-05-08 2013-11-14 Envivo Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
ES2694299T3 (es) 2013-02-07 2018-12-19 Heptares Therapeutics Limited Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4
EA029430B1 (ru) 2013-06-21 2018-03-30 Такеда Фармасьютикл Компани Лимитед Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
CN112898312B (zh) * 2021-01-29 2021-11-12 湖南南新制药股份有限公司 一种稠合多环吡啶酮衍生物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
FR2788982B1 (fr) 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
US20010016677A1 (en) * 1999-02-16 2001-08-23 Dan Russell Poole Incubator with thermoelectric cooler
SI1397366T1 (sl) * 2001-06-01 2007-06-30 Astrazeneca Ab Nov ligand za nikotinske acetilholinske receptorje, koristen v terapiji
US6569865B2 (en) * 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
KR20040099447A (ko) * 2002-04-18 2004-11-26 아스트라제네카 아베 푸릴 화합물
AU2003224545B2 (en) * 2002-04-18 2009-08-13 Astrazeneca Ab Thienyl compounds

Also Published As

Publication number Publication date
HK1079522A1 (en) 2006-04-07
JP4511196B2 (ja) 2010-07-28
ATE477256T1 (de) 2010-08-15
EP1499615B1 (en) 2010-08-11
CN1659170A (zh) 2005-08-24
WO2003087103A1 (en) 2003-10-23
BR0309342A (pt) 2005-02-15
KR20040099448A (ko) 2004-11-26
MXPA04010193A (es) 2005-02-03
EP1499615A1 (en) 2005-01-26
DE60333746D1 (de) 2010-09-23
US20070142419A1 (en) 2007-06-21
ES2348282T3 (es) 2010-12-02
JP2005527588A (ja) 2005-09-15
NO20044997L (no) 2005-01-18
US20110124672A1 (en) 2011-05-26
NZ535978A (en) 2007-10-26
US20050171106A1 (en) 2005-08-04
AU2003224545B2 (en) 2009-08-13
CA2482312A1 (en) 2003-10-23
CN1325499C (zh) 2007-07-11
US7186836B2 (en) 2007-03-06
AU2003224545A1 (en) 2003-10-27

Similar Documents

Publication Publication Date Title
IL164511A0 (en) Heterocyclic compounds
IL164613A0 (en) Thienyl compounds
IL164509A0 (en) Furyl compounds
SE0202463D0 (sv) Novel compounds
MY134568A (en) Cb2 receptor agonists
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
GB0114286D0 (en) Nucleoside Derivatives
MX2007005933A (es) Compuestos de acetamida como fungicidas.
AU2003228770A8 (en) Substituted pyrazolopyrimidines
SE0401971D0 (sv) Piperidne derivatives
PH12013500123A1 (en) Hemiasterlin derivatives and uses thereof
TW200716628A (en) Novel compounds
SE0401970D0 (sv) Novel compounds
TW200643013A (en) Pyrazoles
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
SE0301320D0 (sv) Positive modulators of nicotinic acetylcholine receptors
SE0203070D0 (en) Novel compounds
IL173810A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
GB0229081D0 (en) Multifunctional cationic photoinitiators, their preparation and use
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
GB0212410D0 (en) Organic compounds
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
MXPA06003345A (es) Derivados de aminopiridina como inhibidores de la no-sintasa inducible.
GB0103240D0 (en) Organic compounds